Skip to main content
Signal8
Launch Terminal

Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc.

NASDAQ:ZBIOHealthcare
-1.29%$28.39
AH$28.39+0.00%vs close
Mkt Cap$1.85B
Float31.16M
O/S65.18M
Vol
$ Vol
RVOL
Inst Own93.7%
SI40.2%
Earnings
Dilution
Zenas BioPharma, Inc. logoNASDAQ:ZBIO$28.39-1.29%
Upcoming Catalysts
  • obexelimabPDUFA
    IgG4-RD
    Cash runway at this date: 15mo
    May 27, 2027in 206 days8-K
Phase Distribution
10 lead-sponsored trials·6 active·4 completed
Phase 14
Phase 22
Phase 34

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

    Obexelimab

    IgG4 Related Disease

    Enrollment
    194
    Start
    Jan 2023
    Primary Completion
    Nov 2025
    Completion
    Feb 2029est.
    NCT05662241
  • Phase 3
    Active, not recruiting

    A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

    Obexelimab, Obexelimab

    Warm Autoimmune Hemolytic Anemia

    Enrollment
    134
    Start
    Sep 2023
    Primary Completion
    Jun 2026est.
    Completion
    Aug 2026est.
    NCT05786573
  • Phase 3
    Recruiting

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    Orelabrutinib, Placebo

    Multiple Sclerosis (MS) Primary Progressive

    Enrollment
    705
    Start
    Mar 2026
    Primary Completion
    Jun 2030est.
    Completion
    Jul 2030est.
    NCT07067463
  • Phase 3
    Recruiting

    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    Orelabrutinib, Placebo

    Secondary Progressive Multiple Sclerosis

    Enrollment
    990
    Start
    Mar 2026
    Primary Completion
    Jun 2030est.
    Completion
    Jul 2030est.
    NCT07299019
  • Phase 2
    Active, not recruiting

    A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

    Obexelimab, Placebo

    Systemic Lupus Erythematosus

    Enrollment
    190
    Start
    Sep 2024
    Primary Completion
    Sep 2026est.
    Completion
    Dec 2026est.
    NCT06559163
  • Phase 2
    Active, not recruiting

    A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

    Obexelimab, Placebo

    Relapsing Multiple Sclerosis

    Enrollment
    93
    Start
    Aug 2024
    Primary Completion
    Aug 2025
    Completion
    Feb 2026est.
    NCT06564311
  • Phase 1
    Completed

    A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects

    ZB001 for injection, ZB001 for injection

    Healthy Volunteers

    Enrollment
    24
    Start
    Oct 2022
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT05542303
  • Phase 1
    Completed

    A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

    ZB002, Placebo

    Healthy Volunteers, Rheumatoid Arthritis

    Enrollment
    72
    Start
    Dec 2022
    Primary Completion
    Feb 2026
    Completion
    Feb 2026
    NCT05638854
  • Phase 1
    Completed

    Study of ZB001 in Chinese Patients With Thyroid Eye Disease

    ZB001 for injection, ZB001 for injection

    Thyroid Eye Disease

    Enrollment
    17
    Start
    May 2023
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT05776121
  • Phase 1
    Completed

    A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

    ZB004, Placebo

    Healthy Volunteers

    Enrollment
    40
    Start
    Jun 2023
    Primary Completion
    Mar 2024
    Completion
    Mar 2024
    NCT05794516
Search ClinicalTrials.gov for “Zenas BioPharma”